dolutegravir vs empagliflozin/linagliptin
Side-by-side comparison of dolutegravir and empagliflozin/linagliptin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Recommendation: Your doctor may need to lower your metformin dose or check your blood levels more often.
Tivicay
Glyxambi
TRIUMEQ is a drug that contains three medicines in one pill: dolutegravir, abacavir, and lamivudine. It is used to treat HIV-1 infection in adults and children.
Glyxambi is a drug that combines three medicines to help lower blood sugar in adults with type 2 diabetes. It can also lower the risk of death from heart problems in those with both type 2 diabetes and heart disease.
TRIUMEQ treats HIV-1, the virus that causes AIDS. It helps to lower the amount of virus in your body. This medication can help your body fight infection and can improve your health.
Glyxambi is used to improve blood sugar control in adults with type 2 diabetes. It should be used along with diet and exercise. Glyxambi can also help lower the risk of death caused by heart problems if you have both type 2 diabetes and heart disease. It is not for people with type 1 diabetes.
TRIUMEQ contains three drugs that each work differently to stop HIV from multiplying. Dolutegravir is an integrase strand transfer inhibitor (INSTI). Abacavir and lamivudine are nucleoside analogue reverse transcriptase inhibitors.
Glyxambi works in three ways to lower blood sugar. Empagliflozin helps your kidneys remove sugar from your blood through urine. Linagliptin helps your body release more insulin after meals. Metformin helps to decrease the amount of sugar your liver makes and helps your body use insulin better.
- • Trouble sleeping (insomnia)
- • Headache
- • Feeling tired
- • Upper respiratory infection (like a cold)
- • Urinary tract infection
- • Runny or stuffy nose
- • Diarrhea
- • Constipation
- Pain 1,425
- Anxiety 1,051
- Emotional Distress 1,048
- Anhedonia 942
- Chronic Kidney Disease 701
- Increased blood sugar 146
- Diabetic ketoacidosis 144
- Feeling sick to your stomach 102
- Fungal infection 92
- Weight loss 86
TRIUMEQ can cause serious allergic reactions. If you have a gene called HLA-B*5701, you are more likely to have an allergic reaction. You should be tested for this gene before taking TRIUMEQ. Symptoms can include fever, rash, nausea, vomiting, diarrhea, or stomach pain. Some people can also experience liver problems or a heart attack.
Glyxambi contains metformin, which can cause a serious side effect called lactic acidosis. Lactic acidosis is a buildup of lactic acid in the blood. It can be life-threatening. Get medical help right away if you have symptoms like feeling very weak, tired, or uncomfortable; unusual muscle pain; trouble breathing; stomach pain with nausea and vomiting; feeling cold, especially in your arms and legs; feeling dizzy or lightheaded; or a sudden change in your heartbeat.
Tell your doctor if you are pregnant or plan to become pregnant. There is a pregnancy registry to monitor outcomes in people who take TRIUMEQ during pregnancy. Talk to your doctor about the risks and benefits of taking TRIUMEQ during pregnancy.
Glyxambi is not recommended during the second and third trimesters of pregnancy due to potential harm to the baby's kidneys. It is also not recommended while breastfeeding. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
How to Read This dolutegravir vs empagliflozin/linagliptin Comparison
dolutegravir is classified in the Integrase Strand Transfer Inhibitor drug class, while empagliflozin/linagliptin sits within the SGLT2 / DPP-4 Combination class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, dolutegravir has 5,167 submissions while empagliflozin/linagliptin has 570. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to dolutegravir blocks the kidneys from filtering metformin out of your blood, which makes metformin levels rise. higher levels of metformin increase the risk of a serious health problem called lactic acidosis.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between dolutegravir and empagliflozin/linagliptin - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.